

EUROPEAN PATENT SPECIFICATION

Date of publication of the patent specification:
10.08.88

Int. Cl.: **C 07 H 17/08**

Application number: **86300290.3**

Date of filing: **17.01.86**

Antibacterial derivatives of a neutral macrolide.

Priority: **22.01.85 US 693702**

Date of publication of application:
30.07.88 Bulletin 88/31

Publication of the grant of the patent:
10.08.88 Bulletin 88/32

Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

References cited:
US-A-3 883 507

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1980, pages 3805-3808, American Chemical Society, US; B. ARNOUX et al.: "23672RP, a new macrolide antibiotic from Streptomyces Chryseus. Mass spectrometry study and X-ray structure determination"

Proprietor: **PFIZER INC., 235 East 42nd Street, New York, N.Y. 10017 (US)**

Inventor: **Nagel, Arthur Adam, 66, Inchcliffe Drive, Gales Ferry Connecticut, 06335 (US)**

Representative: **Moore, James William, Dr., Pfizer Limited Ramsgate Road, Sandwich Kent CT13 9NJ (GB)**

EP 0 189 281 B1


Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description**Background of the Invention**

5 This invention relates to new antibacterial agents which are derivatives of a neutral macrolide previously disclosed in U.S. Patent No. 3 857 937 and J. Am. Chem. Soc., 102, 3605 (1980). The novel compounds of the present invention represent changes in the ketone function of the beta-D-4,6-dideoxy-3-ketoallose unit of the macrolide structure.

Summary of the Invention

15 This invention provides new macrolide antibacterial compounds selected from those of the formula




40 wherein R is selected from the group consisting of hydroxyminoethylamino and dimethylamino. Pharmaceutically-acceptable acid addition salts of the aforementioned compounds wherein R is aminoethylamino or dimethylamino are also considered part of the present invention.

Preferred are those compounds where R is dimethylamino; especially preferred is the compound where R is dimethylamino in the beta configuration.

45 Also considered as part of the present invention is a pharmaceutical composition which comprises a pharmaceutically-acceptable carrier and a compound of the present invention wherein said pharmaceutically-acceptable carrier and said compound are present in a weight ratio in the range of from 1 : 6 to 6 : 1.


50 Detailed Description of the Invention

The neutral macrolide from which the compounds of the present invention are derived has the following chemical structure:



The chemical name for this compound is 6,12-dideoxy-15-[(6-deoxy-2,3-di-methyl-beta-D-allopyranosyl)-oxy]-5-0-(4,6-dideoxy-beta-D-erythro-hexopyranos-3-ulos-1-yl)-3-0-(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-8-hydroxy-14-methyl-erythronolide (14S)-11-(2-hydroxy-3-methylbutanoate). In the interest of brevity this neutral macrolide will be referred to as CP-63,693. Further, in describing the chemistry leading to the compounds of the present invention only that portion of the structure where changes take place, namely the beta-D-4-6-dideoxy-3-ketoallose portion, will be depicted.

Treatment of the neutral macrolide CP-63,693 with a ten to fifteen fold excess of ammonium chloride or methylamine hydrochloride in the presence of hydrogen gas and a palladium-on-charcoal catalyst results in the formation of the corresponding C₃' amino and methylamino derivatives, respectively. The reaction is depicted as follows:





This reductive amination reaction is best conducted in a reaction-inert solvent such as methanol or ethanol. The reaction can be conducted at room temperature at a hydrogen pressure of about 146 kg. s. cm. Under these conditions the reaction is generally complete in about 6 - 18 hours.

As is realized, such a reduction can theoretically give rise to the formation of two diastereomers; a substituent on the same side of the ring as the adjacent C₂' hydroxy group would have the alpha configuration, which is represented by a broken line and a substituent on the opposite side of the hydroxy group having the beta configuration, which is represented by a solid line. When both diastereomers are depicted they can be represented by a wavy line.


In the particular reductive amination wherein hydrogen gas is used and palladium-on-charcoal is employed as the catalyst only one of the diastereomers is found. Based on analytical and other findings the isolated diastereomer in each case is assigned the alpha configuration.

When the neutral macrolide CP-63 693 is reacted with ammonium chloride or methylamine and sodium cyanoborohydride is employed as the reducing agent both diastereomers, 1 and 2, are formed, as follows:




30 The reaction is best conducted in a reaction-inert solvent such as methanol using a 50 per cent molar excess of ammonium chloride or methylamine hydrochloride. The use of an equimolar amount of hydride to macrolide will provide the desired product, but an excess as large as 75 % provides an optimum yield of product. Using the aforementioned ratio of starting reagents and conducting the reaction at room temperature provides product after a reaction period of 2 - 3 hours.

35 Treatment of 1 (R = CH₃NH-) with equimolar amounts of formaldehyde and formic acid in a reaction-inert solvent such as chloroform at room temperature results in the formation of an oxazolidine ring between the methylamine moiety and the adjacent hydroxy group as follows:




50 Hydrogenation of 3 with hydrogen gas and a palladium-on-charcoal catalyst at room temperature at 50 p.s.i. provides the alphadimethylamino diastereomer of the present invention as follows:




Treatment of the mixture of **1** and **2** with formaldehyde in chloroform as the reaction-inert solvent results in the conversion of **1** ($R' = CH_3$) to **3** and allows for the separation of the less basic oxazolidine **3** from **2** by selective extraction at pH 2.5.


Reaction of the separated beta-diastereomer **2** ($R' = CH_3$) with formaldehyde and formic acid in chloroform provides, directly, the beta-dimethylamino diastereomer of the present invention, depicted as follows:



20 Reaction of CP-63,693 with a two fold molar excess of sodium borohydride at room temperature in a reaction-inert solvent gives a mixture of both the C_3' -equatorial and axial alcohol **6** as follows:




35 The use of a hindered hydride, such as lithium tri-*t*-butoxyaluminum hydride with CP-63,693 gives a single diastereomer, **7** the α - C_3' hydroxy as follows:




The most useful reaction-inert solvent in the hydride reactions to give the hydroxy compounds of the present invention is tetrahydrofuran. The molar ratio of hydride to macrolide is generally about 2 : 1. The reaction, when conducted at room temperature is generally complete in a few hours.

The reactions leading to the compounds of the present invention are unique in that they appear to selectively take place at the C_3' position of the macrolide in spite of the presence of other functional groups present which could potentially react under the conditions of reductive amination and hydride reduction. This lack of participation by other functional groups is unexpected.

As previously indicated, the compounds of the present invention are useful antibacterial agents. Preferred in that regard are those compounds of the formula



wherein R is dimethylamino. Especially preferred is the compound of the beta configuration:



Compound 5 demonstrates enhanced activity over the parent macrolide against Hemophilus and an increase in the plasma half-life.

In the utilization of the chemotherapeutic activity of those compounds of the present invention which form salts, it is preferred, of course, to use pharmaceutically-acceptable salts. Although water-insolubility, high toxicity, or lack of crystalline nature may make some particular salt species unsuitable or less desirable for use as such in a given pharmaceutical application, the water insoluble or toxic salts can be converted to the corresponding pharmaceutically-acceptable bases by decomposition of the salt or, alternately, they can be converted to any desired pharmaceutically-acceptable acid addition salt.

Examples of acids which provide pharmaceutically-acceptable anions are hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, or sulfurous, phosphoric, acetic, lactic, citric, tartaric, succinic, maleic, gluconic and aspartic acids.

The novel derivatives described herein exhibit in vitro activity against a variety of Gram-positive microorganisms such as Staphylococcus aureus and Streptococcus pyogenes and against certain Gram-negative microorganisms such as those of spherical or ellipsoidal shape (cocci). Their activity is readily demonstrated by in vitro tests against various microorganisms in a brain-heart infusion medium by the usual two-fold serial dilution technique. Their in vitro activity renders them useful for topical application in the form of ointments, creams and the like; for sterilization purposes, e.g., sick-room utensils; and as industrial antimicrobials, for example, in water treatment, slime control, paint and wood preservation.

For in vitro use, e.g. or topical application, it will often be convenient to compound the selected product with a pharmaceutically-acceptable carrier such as vegetable or mineral oil or an emollient cream. Similarly, they may be dissolved or dispersed in liquid carriers or solvents, such as water, alcohol, glycols or mixtures thereof or other pharmaceutically-acceptable inert media; that is media which have no harmful effect on the active ingredient. For such purposes, it will be generally acceptable to employ concentrations of active ingredients of from about 0.01 percent to about 10 percent by weight based on total composition.


Additionally, many compounds of this invention are active versus Gram-positive and certain Gram-negative microorganism in vivo such as Staphylococcus aureus via the parenteral route of administration in animals, including man. Their in vivo activity is more limited as regards susceptible organisms and is determined by the usual procedure which comprises mice of substantially uniform weight with the test organism and subsequently treating them orally or subcutaneously with the test compound. In practice, the mice, e.g. 10, are given an intraperitoneal inoculation of suitably diluted cultures containing approximately 1 to 10 times the LD₁₀₀

(the lowest concentration of organisms required to produce 100 % deaths). Control tests are simultaneously run in which mice receive inoculum of lower dilutions as a check on possible variation in virulence of the test organism. The test compound is administered 0.5 hour postinoculation, and is repeated 4, 24 and 48 hours later. Surviving mice are held for four days after the last treatment and the number of survivors is noted.

5 When used in vivo, the novel compounds of the present invention wherein R is hydroxy can be administered orally or parenterally. Those novel compounds wherein R is amino, methylamino and dimethylamino are best administered parenterally, i.e., by subcutaneous or intramuscular injection. The effective oral or parenteral dose is generally from about 1 mg/kg to about 200 mg/kg of body weight per day. The favored dosage range is from about 5 mg/kg to about 100 mg/kg of body weight per day and the preferred range from about 5 mg/kg to 10 about 50 mg/kg of body weight per day. Vehicles suitable for parenteral injection may be either aqueous such as water, isotonic saline, isotonic dextrose, Ringers' solution, or non-aqueous such as fatty oils of vegetable origin (cotton seed, peanut oil, corn, sesame), dimethyl-sulfoxide and other non-aqueous vehicles which will not interfere with therapeutic efficiency of the preparation and are non-toxic in the volume or proportion used (glycerol, propylene glycol, sorbitol). Additionally, compositions suitable for extemporaneous preparation of 15 solutions prior to administration may advantageously be made. Such compositions may include liquid diluents, for example, propylene glycol, diethyl carbonate, glycerol, sorbitol, etc.; buffering agents, hyaluronidase, local anesthetics and inorganic salts to afford desirable pharmacological properties. These compounds may also be combined with various pharmaceutically-acceptable inert carriers including solid diluents, aqueous vehicles, non-toxic organic solvents in the form of capsules, tablets, lozenges, troches, dry mixes, suspensions, 20 solutions, elixirs and parenteral solutions or suspensions. In general, the compounds are used in various dosage forms at concentration levels ranging from about 0.5 percent to about 90 percent by weight of the total composition.

The following examples are provided solely for the purpose of illustration and are not to be construed as limitations of this invention, many variations of which are possible without departing from the spirit or scope 25 thereof.


30 Example 1




40 (Compound 1, R = alpha NH₂)

A mixture of 100 mg (0.1 mmole) of CP-63,693, 53 mg (1 mmole) of ammonium chloride and 50 mg of 10 % palladium-on-charcoal in 5 ml of methanol was shaken in an atmosphere of hydrogen gas at room temperature at an initial pressure of 148 kg. s. cm. After 18 hours the reaction mixture was filtered and the filtrate 45 concentrated in vacuo to a foam. The residue was dissolved in a mixture of ethyl acetate-water and the pH adjust to 2.5 with 6N hydrochloric acid. The aqueous phase was separated and aqueous 1.1N sodium hydroxide added until the pH was 5.0. Fresh ethyl acetate was added and the mixture shaken. The aqueous layer was separated and the pH adjusted to 9.5 with 1.1N aqueous sodium hydroxide. Again, fresh ethyl acetate was 50 added and the mixture shaken. The organic phase was separated, dried and concentrated under vacuum to give 60 mg of the desired product.

| Mass Spectrum: | M/E | Cal'd for | Assignment |
|----------------|---------------------|--|-----------------|
| | 175.0963 (± 0.7ppm) | C ₈ H ₁₅ O ₄ | mycinose sugar |
| | 145.0854 (± 1.1ppm) | C ₇ H ₁₃ O ₃ | cladinose sugar |
| | 130.0867 (± 0.0ppm) | C ₆ H ₁₂ NO ₂ | |




Example 2

(Compound 1, R = alpha CH₃NH-)

- To 500 mg (0.51 mmole) of CP-63,693 and 500 mg (7.4 mmoles) of methylamine hydrochloride in 15 ml of methanol was added 100 mg of 10 % palladium-on-charcoal, and the resulting mixture shaken in a hydrogen atmosphere at room temperature and an initial pressure of 146 kg. s. cm. for 18 hours. The mixture was filtered and the filtrate concentrated *in vacuo* to dryness. The residue was dissolved in a mixture of water-ethyl acetate and the pH adjusted to 3.0 with 6N hydrochloric acid. The aqueous phase was separated, the pH adjusted to 10 and shaken with fresh ethyl acetate. The organic phase was separated, dried and concentrated to give 460 mg of the crude product. Recrystallization from diethyl ether gave 230 mg of pure product. An additional 170 mg of product was obtained by careful concentration of the mother liquor.


| Mass Spectrum: | M/e | Calc'd for | Assignment |
|--------------------------|---|--|------------|
| | 144.1023 | C ₇ H ₁₄ NO ₂ | |
| NMR (CDCl ₃) | δ 2.35 (s,3H) 3.48 (s,3H) 3.60 (s,3H) | NHCH ₃ mycinose OCH ₃ | |

Example 3

(Compound 2, R = beta CH₃NH-)


- To 500 mg (0.51 mmole) of CP-63,693 in 15 ml of methanol was added 500 mg (7.4 mmoles) of methylamine hydrochloride and the mixture allowed to stand at room temperature for 20 minutes. To the resulting solution was added 50 mg (0.79 mmole) of sodium cyanoborohydride and the reaction mixture allowed to stir for 60 minutes at room temperature. The reaction mixture was treated with water and ethyl acetate and the pH adjusted to 9.5 with 1N aqueous sodium hydroxide solution. The organic phase was separated, combined with water and the pH adjusted to 2.5. The aqueous phase was extracted with fresh ethyl acetate at pH 5.5, 6.5, 7.0, 7.4, 7.8 and 10. The ethyl acetate from the extraction at 10 was dried and concentrated *in vacuo* to give 90 mg of the desired product.

0 189 281

| Mass Spectrum: | M/e | Calc'd for | Assignment |
|----------------|---------------------------|--|--|
| | 144.1010 (± 1.5 ppm) | C ₇ H ₁₄ NO ₂ |  |

| NMR (C ₃ DCl ₃) | δ | |
|--|--------------|--|
| | 2.38 (s, 3H) | } NHCH ₃ mycinose OCH ₃ |
| | 3.48 (s, 3H) | |
| | 3.61 (s, 3H) | |


Example 4



(Compound 4, R = α -N(CH₃)₂)


The product of Example 2 (170 mg, 0.17 mmole), 0.14 ml (1.7 mmoles) of 37 % aqueous formaldehyde and 1.7 ml (0.17 mmole) of 1.1M formic acid in chloroform were added to 5 ml of chloroform and the reaction mixture allowed to stir at room temperature for 60 minutes. The reaction was diluted with water and the pH adjusted to 9.5 with 1N aqueous sodium hydroxide. The organic layer was separated, dried and concentrated under vacuum to give 170 mg (Compound 3).

The residue was dissolved in 10 ml of methanol to which was subsequently added 100 mg of 10 % palladium-on-charcoal. The resulting mixture was shaken in a hydrogen atmosphere at an initial pressure of 50 p.s.i. After 18 hours the catalyst was filtered and the filtrate concentrated *in vacuo* to dryness. The residue was dissolved in ethyl acetate to which was added water, and the pH adjusted to 2.5 with 1N hydrochloric acid. The aqueous phase was separated and extracted with fresh ethyl acetate at pH 5.5, 6.2 and 10. The organic phase from extraction at pH 10 was dried and concentrated to give 120 mg of the desired product.

| Mass Spectrum: | M/e | Calc'd for | Assignment |
|----------------|---------------------------|--|--|
| | 158.1168 (± 1.3 ppm) | C ₈ H ₁₆ NO ₂ |  |

| NMR (CDCl ₃) | δ | |
|--------------------------|-------------|----------------------------------|
| | 2.3 (s, 6H) | N(CH ₃) ₂ |

Exemple 5



To 15 ml of methanol was added 500 mg (0.51 mmole) of CP-63,693 and 500 mg (7.4 mmoles) of methylamine hydrochloride. After stirring at room temperature for 15 minutes 50 mg (0.79 mmole) of sodium borohydride was added and the resulting reaction mixture allowed to stir at ambient temperature for 2 hours. The reaction mixture was treated with water and ethyl acetate and the pH adjusted to 10 with 1N aqueous sodium hydroxide. The organic layer was separated, dried and concentrated to dryness. The residue was dissolved in fresh ethyl acetate, water added and the pH adjusted to 2.5. The aqueous phase was separated, combined with fresh ethyl acetate and the pH adjusted to 10. The organic phase was separated, dried and concentrated to give 380 mg of product which, by thin layer chromatography, contains the two C₃' diastereomers 1 and 2 (R' = CH₃).

To the residue was added 5 ml of chloroform and 50.3 ml of 37 % formaldehyde solution and the solution allowed to stir for 60 minutes at room temperature. Water was added and the pH adjusted to 2.5. The aqueous phase was separated, dried and concentrated in vacuo to give 130 mg of product (compound 2, R = beta -NHCH₃).

The residue was combined with 2.6 ml (0.26 mmole) of 1.1M formic acid in chloroform and 5 drops of 37 % formaldehyde and the reaction mixture heated to reflux for 2 hours. The reaction was treated with water, the pH adjusted to 3.0 and ethyl acetate added. The pH was adjusted to 10 and the organic layer separated, dried and concentrated in vacuo to give 60 mg of the final product (compound 5, R = beta -N(CH₃)₂).

| Mass Spectrum | | | |
|--------------------------|--------------|---|---------------------------|
| (cpd 5) | M/e | Calc'd for | Assignment |
| | 158.1181 | C ₈ H ₁₆ O ₂ N | |
| | | | |
| NMR (CDCl ₃) | | | |
| | δ | | |
| | 2.28 (s, 6H) | } N(CH ₃) ₂ | mycinose OCH ₃ |
| | 3.48 (s, 3H) | | |
| | 3.62 (s, 3H) | | |

55 ; Exemple 6




65 Diastereomers 1 and 2 R = NH₂

0 189 281

The procedure of Example 3 is repeated starting with 500 mg (0.51 mmole) of CP-63,693, 39.8 mg (0.75 mmole) of ammonium chloride, 50 mg of sodium cyanoborohydride and 15 ml of methanol. On completion of the reaction water and ethyl acetate are added to the reaction and the pH adjusted to 9.5 The ethyl acetate layer is separated, dried and concentrated under vacuum to give a mixture of the alpha and beta diastereomers, 1 and 2, R = NH₂.


Example 7



(Compound 7, R = alpha -OH)


A mixture of 100 mg (0.1 mmole) of CP-63,693 and 52 mg (0.2 mmole) of lithium tri-t-butoxyaluminumhydride in 10 ml of tetrahydrofuran was allowed to stir at room temperature for 1 hour. The reaction mixture was treated with water and ethyl acetate and the pH adjusted to 10. The ethyl acetate was separated and the aqueous layer extracted (3x) with fresh ethyl acetate. The organic extracts were combined, dried over sodium sulfate and concentrated to give 90 mg of product.

| Mass Spectrum: | M/e | Calc'd for | Assignment |
|----------------|---------------------|---|------------|
| | 131.0704 (± 0.4ppm) | C ₆ H ₁₁ O ₃ | |



| NMR: | δ | |
|------|-------------|-----------------------------|
| | 3.52 (s,3H) | } mycinose OCH ₃ |
| | 3.65 (s,3H) | |


Example 8



Diastereomers 6 and 7, R = OH


0189281

To a solution of 100 mg (0.1 mmole) of CP-63,693 in 5 ml of tetrahydrofuran was added 3.8 mg (0.025 mmole) of sodium borohydride and the resulting reaction mixture allowed to stir at room temperature for 1 hour. The solvent was evaporated and the residue dissolved in 50 ml of ethyl acetate-water (1 : 1, v : v). The organic phase was separated, dried and concentrated to give 89 mg of an amorphous solid which, by thin layer chromatography (chloroform-methanol-ammonium hydroxide; 5 : 1 : 1) indicated a 50 - 50 mixture of the desired two diastereomers.

| Mass Spectrum: | M/e | Calc'd for | Assignment |
|----------------|---------------------------|---|--|
| | 131.0704 (± 0.4 ppm) | C ₆ H ₁₁ O ₃ |  |

Claims for the Contracting States: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A compound of the formula



wherein R is selected from the group consisting of hydroxy, amino, methylamino and dimethylamino and the pharmaceutically-acceptable acid addition salts of those wherein R is aminoethylamino or dimethylamino.

2. A compound of claim 1, wherein R is dimethylamino.

3. The compound of claim 2, wherein R is beta dimethylamino.

4. A compound of claim 1 for use in treating a bacterial infection in a mammalian subject.


5. A pharmaceutical composition, which comprises a pharmaceutically-acceptable carrier and a compound according to claim 1, wherein said pharmaceutically-acceptable carrier and said compound are present in a weight ratio in the range of 1 : 6 to 6 : 1.

6. Use of a compound of claim 1 for the manufacture of a medicament for the treatment of bacterial infections.


Claims for the Contracting State; AT

1. A process for preparing a compound of the formula

0 189 281




wherein R is NH₂ or NHCH₃ which comprises reacting a compound of the formula




with
a) R₁NH₂·HCl, where R₁ is H or CH₃, in the presence of hydrogen and a catalytic amount of palladium-on-charcoal in a reaction inert solvent to give the product as the alpha configuration or,
b) R₁NH₂·HCl, where R₁ is H or CH₃, and sodium borohydride in a reaction inert solvent to give the product of both alpha and beta configuration.
2. A process for preparing a compound of the formula

0 189 281



which comprises reacting a compound of the formula




50 with hydrogen in the presence of a palladium-on-charcoal catalyst.
 3. A process for preparing a compound of the formula

55


60

65

0 189 281




which comprises reacting a compound of the formula




with formic acid and formaldehyde in a reaction inert solvent.

4. A process for preparing a compound of the formula



0 189 281

wherein R₂ is hydroxy, which comprises reacting a compound of the formula




with

a) sodium borohydride in a reaction inert solvent to give the product of both the alpha and beta configuration or,

b) lithium tri-*t*-butoxyaluminum hydride in a reaction inert solvent to give the product of the alpha configuration.


5. A compound of the formula



wherein R is selected from the group consisting of hydroxy, amino, methylamino and dimethylamino, and the pharmaceutically-acceptable acid addition salts of those wherein R is amino, methylamino or dimethylamino.

Patentansprüche für die Vertragsstaaten: BE, CH, DE, FR, GB, LT, LI, LU, NL SE:

1. Verbindung der Formel



worin R ausgewählt ist aus der Gruppe bestehend aus Hydroxy, Amino, Methylamino und Dimethylamino, und die pharmazeutisch annehmbaren Säureadditionssalze jener, worin R Amino, Methylamino oder Dimethylamino ist.

2. Verbindung nach Anspruch 1, worin R Dimethylamino ist.

3. Verbindung nach Anspruch 2, worin R β -Dimethylamino ist.


4. Verbindung nach Anspruch 1 zur Verwendung beim Behandeln einer Bakterieninfektion in einem Säuger.

5. Pharmazeutische Zusammensetzung, die einen pharmazeutisch annehmbaren Träger und eine Verbindung nach Anspruch 1 umfaßt, wobei der pharmazeutisch annehmbare Träger und die Verbindung in einem Gewichtsverhältnis im Bereich von 1 : 6 bis 6 : 1 anwesend sind.


6. Verwendung einer Verbindung nach Anspruch 1 für die Herstellung eines Medikaments zur Behandlung von Bakterieninfektionen.

Patentansprüche für den Vertragsstaat AT:

1. Verfahren zum Herstellen einer Verbindung der Formel



worin R NH_2 oder NHCH_3 ist, welches das Umsetzen einer Verbindung der Formel




mit


a) $R_1NH_2 \cdot HCl$, worin R_1 H oder CH_3 ist, in Anwesenheit von Wasserstoff und eines katalytischen Anteils von Palladium auf Kohle in einem reaktionsinerten Lösungsmittel, wobei das Produkt in α -Konfiguration erhalten wird, oder

b) $R_1NH_2 \cdot HCl$, worin R_1 H oder CH_3 ist, und Natriumborhydrid in einem reaktionsinerten Lösungsmittel, wobei das Produkt sowohl in α - als auch in β -Konfiguration erhalten wird, umfaßt.


2. Verfahren zum Herstellen einer Verbindung der Formel



welches das Umsetzen einer Verbindung der Formel



25 mit Wasserstoff in Anwesenheit eines Palladium auf Kohle-Katalysators umfaßt.
3. Verfahren zum Herstellen einer Verbindung der Formel



50 welches das Umsetzen einer Verbindung der Formel

55

60

65


0 189 281

5

10

15

20



mit Ameisensäure und Formaldehyd in einem reaktionsinerten Lösungsmittel umfaßt.
4. Verfahren zum Herstellen einer Verbindung der Formel


25

30

35

40

45



worin R_2 Hydroxy ist, welches das Umsetzen einer Verbindung der Formel


50

55

60

65

0 189 281




mit

a) Natriumborhydrid in einem reaktionsinerten Lösungsmittel, wobei das Produkt sowohl in α - als auch in β -Konfiguration erhalten wird, oder

b) Lithiumtri-tert.butoxyaluminiumhydrid in einem reaktionsinerten Lösungsmittel, wobei das Produkt in α -Konfiguration erhalten wird, umfaßt.

5. Verbindung der Formel




worin R ausgewählt ist aus der Gruppe bestehend aus Hydroxy, Amino, Methylamino und Dimethylamino und die pharmazeutisch annehmbaren Säureadditionssalze jener, worin R Amino, Methylamino oder Dimethylamino ist.


Revendications pour l'Etat contractant: AT

1. Procédé de préparation d'un composé de formule

0 189 281



dans laquelle R est un groupe NH₂ ou NHCH₃ qui consiste à faire réagir un composé de formule



avec

a) un composé R₁NH₂.HCl dans lequel R₁ représente H ou CH₃, en présence d'hydrogène et d'une quantité catalytique de palladium fixé sur du charbon dans un solvant inerte vis-à-vis de la réaction pour obtenir le produit ayant la configuration alpha, ou bien

b) un composé R₁NH₂.HCl dans lequel R₁ représente H ou CH₃, et le borohydrure de sodium dans un solvant inerte vis-à-vis de la réaction pour obtenir le produit de configuration alpha et de configuration bêta.

2. Procédé de préparation d'un composé de formule

0 189 281

5

10

15

20

25

30

35

40


45

50


55

60

65



qui consiste à faire réagir un composé de formule



avec l'hydrogène en présence d'un catalyseur au palladium fixé sur du charbon.

3. Procédé de préparation d'un composé de formule


0 189 281

5

10

15

20




qui consiste à faire réagir un composé de formule

25

30

35

40



45

avec l'acide formique et le formaldéhyde dans un solvant inerte vis-à-vis de la réaction.

4. Procédé de préparation d'un composé de formule


50

55


60

65

0 189 281



dans laquelle R₂ est un groupe hydroxy, qui consiste à faire réagir un composé de formule



avec


a) le borohydrure de sodium dans un solvant inerte vis-à-vis de la réaction pour obtenir le produit de la configuration alpha et de la configuration bêta ou bien,

b) l'hydru de lithium et de tri-tertio-butoxyaluminium dans un solvant inerte vis-à-vis de la réaction pour obtenir le produit de la configuration alpha.

5. Composé de formule

0 189 281

5
10
15
20



25


dans laquelle R est choisi dans le groupe comprenant les radicaux hydroxy, amino, méthylamino et diméthylamino, et les sels d'addition d'acides pharmaceutiquement acceptables pour les cas où R est un radical amino, méthylamino ou diméthylamino.

30

Revendications pour les Etats contractants DE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Composé de formule

35
40
45
50



55

dans laquelle R est choisi dans le groupe formé des radicaux hydroxy, amino, méthylamino et diméthylamino, et les sels d'addition d'acides pharmaceutiquement acceptables pour les cas où R est un groupe amino, méthylamino ou diméthylamino.

60

2. Composé suivant la revendication 1, dans lequel R est le groupe diméthylamino.

3. Composé suivant la revendication 2, dans lequel R est le groupe bêta-diméthylamino.

4. Composé suivant la revendication 1, destiné à être utilisé dans le traitement d'une infection bactérienne chez un mammifère.

5. Composition pharmaceutique, qui comprend un support pharmaceutiquement acceptable et un composé suivant la revendication 1, le support pharmaceutiquement acceptable et le composé étant présents dans un rapport en poids compris dans l'intervalle de 1 : 6 à 6 : 1.

65

6. Utilisation d'un composé suivant la revendication 1, pour la préparation d'un médicament destiné au traitement d'infections bactériennes.